|
Larotaxel
|
|
| Systematic (IUPAC) name | |
| (2α,3ξ,4α,5β,7α,10β,13α)-4,10-bis(acetyloxy)-13-({(2R,3S)-3-
[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1- hydroxy-9-oxo-5,20-epoxy-7,19-cyclotax-11-en-2-yl benzoate |
|
| Identifiers | |
| CAS number | |
| ATC code | none |
| PubChem | |
| Chemical data | |
| Formula | C45H57NO16 |
| Mol. mass | 867.93 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Larotaxel is a drug of the taxan type, used in chemotherapy.
| This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
|
|||||||||||||||||||||||||||
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)




